Scott Kahn Acquires 37,500 Shares of XGN
Scott Kahn purchased 37,500 shares of XGN on June 9, 2026.
Key Points
- Scott Kahn bought 37,500 shares of XGN on June 9, 2026, reflecting insider confidence.
- XGN shares traded near $4.45 on Monday, with active institutional involvement.
- Analysts maintain a positive outlook on XGN, with BTIG setting an $8 price target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Scott Kahn increased his stake in XGN by purchasing 37,500 shares on June 9, 2026. This insider transaction comes amid a period of active institutional trading in the company's stock.
Other Institutional Activity in XGN
Several institutional investors have recently adjusted their positions in XGN. Wexford Capital LP increased its holdings by 326,077 shares, bringing its total to 792,855 shares valued at about $2,378,565, marking a 69.9% increase. Acadian Asset Management LLC also boosted its stake by 274,666 shares, now holding 689,114 shares worth approximately $2,061,000, a 66.3% rise. Vanguard Capital Management LLC opened a new position with 678,652 shares, valued at $2,035,956. Meanwhile, Nano Cap New Millennium Growth Fund LP significantly increased its holdings by 335,000 shares to 585,000 shares, a 134% increase in its position.
Exagen Inc. Stock Down 39.8%
Shares of XGN traded near $4.45 on Monday. The company's stock has seen active trading from both insiders and institutions recently. XGN's current market conditions are being closely watched by investors and analysts alike.
$XGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Exagen Inc.
On June 9, 2026, Scott Kahn, along with Frank Stokes and Chas McKhann, each purchased 37,500 shares of XGN. These transactions were not part of a planned trading program. Earlier in the year, on March 12, 2026, John Aballi, President and CEO, bought 100,000 shares at $3.16 per share and an additional 150,000 shares at no cost specified. Jeffrey Black, the Chief Financial Officer, also acquired 75,000 shares at $3.16 per share on the same date.
Analysts Set New Price Targets
On May 12, 2026, BTIG maintained its buy rating on XGN with a price target of $8. Canaccord Genuity also upheld its buy rating with the same target on April 20, 2026. The consensus among analysts remains positive, with a strong buy recommendation and a mean price target reflecting optimism about the company's future prospects.
Bottom Line
Scott Kahn's recent purchase of XGN shares adds to a series of insider buys, suggesting confidence in the company's prospects. Institutional investors are actively adjusting their positions, reflecting varied strategies. Analysts continue to support the stock with favorable ratings and price targets, indicating a positive outlook despite the stock's current trading range.
Get Exagen Inc. alerts
New 13F filings, insider trades, and analyst moves on $XGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.